NCT04862273View on ClinicalTrials.gov

Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis

Active, not recruitingOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

November 1, 2023

Study Completion Date

November 30, 2024

Conditions
Heart Failure NYHA Class IIHeart Failure NYHA Class IIIHeart Failure NYHA Class IVHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection FractionHypertrophy, Left VentricularCardiac Amyloidosis
Interventions
DIAGNOSTIC_TEST

Native T1 CMR

Observed method

DIAGNOSTIC_TEST

Web-based ATTR probability estimator (Pfizer, New York)

Observed method

DIAGNOSTIC_TEST

99mTc-DPD scintigraphy

Reference method

DIAGNOSTIC_TEST

Laboratory screening for multiple myeloma / AL amyloidosis

Reference method

PROCEDURE

Cardiac biopsy

If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive

Trial Locations (1)

04103

University of Leipzig, Leipzig

All Listed Sponsors
lead

University of Leipzig

OTHER